Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285310 · ClinicalTrials.gov registry record · Phase 2
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT01285310 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 237 participants.
The verdict
NCT01285310, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen joints, pain, physical function and structure) in treated patients who have had an inadequate response to Methotrexate.
Interventions
- DRUG Placebo
- DRUG Apremilast 30 mg
- DRUG Apremilast 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2010-12-09 |
| Est. Completion | 2012-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285310
The ClinicalTrials.gov registry entry for NCT01285310 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01285310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285310 about?
NCT01285310 is a clinical study titled "Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis". The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen joints, pain, physical function and structure) in treated patients who h...
What is the current status of trial NCT01285310?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2010-12-09. Estimated completion is 2012-09-10.
What interventions are being tested in trial NCT01285310?
The interventions under investigation include: Placebo (DRUG), Apremilast 30 mg (DRUG), Apremilast 20 mg (DRUG).
Who is sponsoring clinical trial NCT01285310?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.